RhoVac

News

Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate

News

Sanofi's CEO says adding to the group's pipeline through M&A and licensing will be "critical" as it prepares for generic competition to Dupixent.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.